Skip to main content

CORRECTION article

Front. Genet., 26 January 2024
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 | https://doi.org/10.3389/fgene.2024.1357409

Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

This article is a correction to:

  1. A Comprehensive Analysis of HAVCR1 as a Prognostic and Diagnostic Marker for Pan-Cancer

    1. Read original article
Sheng Liu&#x;Sheng Liu1†Wenting Tang,&#x;Wenting Tang2,3†Jing Cao&#x;Jing Cao4†Mei ShangMei Shang1Sun HengchangSun Hengchang1Jiao Gong Jiao Gong1*Bo Hu Bo Hu1*
  • 1Department of Laboratory Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • 2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen Cancer Center, Guanghzou, China
  • 3Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
  • 4Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

A Corrigendum on
A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

by Liu S, Tang W, Cao J, Shang M, Sun H, Gong J and Hu B (2022). Front. Genet. 13:904114. doi: 10.3389/fgene.2022.904114

In the published article, there was an error in the Funding statement. The funding number for The Science and Technology Program of Guangzhou was incorrectly given as “2019-02-01-06-3001-0005”. The correct number is “201903010039”. The corrected Funding statement appears below.

Funding

“This project was supported by: The Science and Technology Program of Guangzhou (201903010039); R&D Plan of Key Areas in Guangdong Province (2019B020231001); Urban Area (High Tech Zone) Joint COVID-19 Infection Emergency Research Project (2020Q-P016).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: HAVCR1, prognosis, diagnostic, liver hepatocellular carcinoma, pancreatic adenocarcinoma

Citation: Liu S, Tang W, Cao J, Shang M, Hengchang S, Gong J and Hu B (2024) Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer. Front. Genet. 15:1357409. doi: 10.3389/fgene.2024.1357409

Received: 18 December 2023; Accepted: 15 January 2024;
Published: 26 January 2024.

Edited and reviewed by:

Anton A. Buzdin, European Organisation for Research and Treatment of Cancer, Belgium

Copyright © 2024 Liu, Tang, Cao, Shang, Hengchang, Gong and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bo Hu, hubo@mail.sysu.edu.cn; Jiao Gong, gongjiao@mail2.sysu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.